NasdaqGS:UTMD

Stock Analysis Report

Executive Summary

Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry in the United States, Europe, and internationally.

Rewards

PE ratio (28.8x) is below the Medical Equipment industry average (46.6x)

Earnings have grown 5.8% per year over the past 5 years

Risk Analysis

High level of non-cash earnings



Snowflake Analysis

Flawless balance sheet with acceptable track record.


Similar Companies

Share Price & News

How has Utah Medical Products's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: UTMD has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-0.1%

UTMD

-0.06%

US Medical Equipment

0.6%

US Market


1 Year Return

25.3%

UTMD

25.1%

US Medical Equipment

20.8%

US Market

Return vs Industry: UTMD matched the US Medical Equipment industry which returned 25.1% over the past year.

Return vs Market: UTMD exceeded the US Market which returned 20.8% over the past year.


Shareholder returns

UTMDIndustryMarket
7 Day-0.1%-0.06%0.6%
30 Day8.8%3.7%2.5%
90 Day7.4%4.2%4.9%
1 Year26.9%25.3%26.2%25.1%23.5%20.8%
3 Year61.5%55.4%91.7%86.1%46.5%37.0%
5 Year90.5%77.1%117.6%93.8%64.6%46.5%

Price Volatility Vs. Market

How volatile is Utah Medical Products's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Utah Medical Products undervalued compared to its fair value and its price relative to the market?

28.8x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: UTMD ($106.42) is trading above our estimate of fair value ($75.87)

Significantly Below Fair Value: UTMD is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: UTMD is good value based on its PE Ratio (28.8x) compared to the Medical Equipment industry average (46.6x).

PE vs Market: UTMD is poor value based on its PE Ratio (28.8x) compared to the US market (18.6x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate UTMD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: UTMD is good value based on its PB Ratio (4.2x) compared to the US Medical Equipment industry average (4.2x).


Next Steps

Future Growth

How is Utah Medical Products forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Utah Medical Products has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Utah Medical Products performed over the past 5 years?

5.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: UTMD has a high level of non-cash earnings.

Growing Profit Margin: UTMD's current net profit margins (30.7%) are higher than last year (29.8%).


Past Earnings Growth Analysis

Earnings Trend: UTMD's earnings have grown by 5.8% per year over the past 5 years.

Accelerating Growth: UTMD's earnings growth over the past year (8.9%) exceeds its 5-year average (5.8% per year).

Earnings vs Industry: UTMD earnings growth over the past year (8.9%) underperformed the Medical Equipment industry 28.3%.


Return on Equity

High ROE: UTMD's Return on Equity (14.5%) is considered low.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Utah Medical Products's financial position?


Financial Position Analysis

Short Term Liabilities: UTMD's short term assets ($49.5M) exceed its short term liabilities ($3.7M).

Long Term Liabilities: UTMD's short term assets ($49.5M) exceed its long term liabilities ($5.4M).


Debt to Equity History and Analysis

Debt Level: UTMD is debt free.

Reducing Debt: UTMD has no debt compared to 5 years ago when its debt to equity ratio was 9.3%.

Debt Coverage: UTMD has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: UTMD has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: UTMD has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if UTMD's debt is covered by short term assets.


Next Steps

Dividend

What is Utah Medical Products's current dividend yield, its reliability and sustainability?

1.05%

Current Dividend Yield


Dividend Yield vs Market

company1.1%marketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: UTMD's dividend (1.05%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.43%).

High Dividend: UTMD's dividend (1.05%) is low compared to the top 25% of dividend payers in the US market (3.71%).


Stability and Growth of Payments

Stable Dividend: UTMD's dividends per share have been stable in the past 10 years.

Growing Dividend: UTMD's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (29.8%), UTMD's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

What is the CEO of Utah Medical Products's salary, the management and board of directors tenure and is there insider trading?

22.4yrs

Average board tenure


CEO

Kevin Cornwell (72yo)

27yrs

Tenure

US$501,300

Compensation

Mr. Kevin L. Cornwell has been the Chairman of the Board at Utah Medical Products Inc. since 1996 and its President and Chief Executive Officer since December 1992. Mr. Cornwell has been Secretary of Utah  ...


CEO Compensation Analysis

Compensation vs Market: Kevin's total compensation ($USD501.30K) is below average for companies of similar size in the US market ($USD1.69M).

Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.


Board Age and Tenure

22.4yrs

Average Tenure

72yo

Average Age

Experienced Board: UTMD's board of directors are seasoned and experienced ( 22.4 years average tenure).


Insider Trading

Insider Buying: UTMD insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$285,50613 Dec 19
Kevin Cornwell
EntityIndividual
Role
Chief Executive Officer
Chairman
Shares2,668
Max PriceUS$107.05
SellUS$86,13529 Nov 19
Kevin Cornwell
EntityIndividual
Role
Chief Executive Officer
Chairman
Shares800
Max PriceUS$107.67
SellUS$70,96219 Nov 19
Barbara Payne
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares694
Max PriceUS$102.25
SellUS$62413 Nov 19
Barbara Payne
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares6
Max PriceUS$104.00
SellUS$178,52707 Nov 19
Kevin Cornwell
EntityIndividual
Role
Chief Executive Officer
Chairman
Shares1,667
Max PriceUS$107.10
SellUS$32,10007 Nov 19
Brian Koopman
EntityIndividual
Role
Chief Financial Officer
Principal Financial Officer & Controller
Shares300
Max PriceUS$107.00
SellUS$130,42628 Feb 19
Barbara Payne
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares1,521
Max PriceUS$85.75
SellUS$35628 Feb 19
Barbara Payne
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares4
Max PriceUS$89.00
SellUS$9222 Feb 19
Barbara Payne
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares1
Max PriceUS$92.00
SellUS$225,62116 Feb 19
Barbara Payne
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares2,445
Max PriceUS$92.29
SellUS$2,12816 Feb 19
Barbara Payne
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares23
Max PriceUS$92.50

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Kevin Cornwell (72yo)

    Chairman

    • Tenure: 27yrs
    • Compensation: US$501.30k
  • Brian Koopman

    Principal Financial Officer & Controller

    • Tenure: 1.7yrs
    • Compensation: US$120.34k

Board Members

  • Kevin Cornwell (72yo)

    Chairman

    • Tenure: 27yrs
    • Compensation: US$501.30k
  • Paul Richins (59yo)

    Director

    • Tenure: 21.9yrs
    • Compensation: US$176.30k
  • Ernst Hoyer (81yo)

    Lead Director

    • Tenure: 0yrs
    • Compensation: US$32.00k
  • Barbara Payne (72yo)

    Independent Director

    • Tenure: 22.9yrs
    • Compensation: US$25.00k
  • James Beeson (77yo)

    Independent Director

    • Tenure: 12.8yrs
    • Compensation: US$25.00k

Company Information

Utah Medical Products, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Utah Medical Products, Inc.
  • Ticker: UTMD
  • Exchange: NasdaqGS
  • Founded: 1978
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$396.002m
  • Shares outstanding: 3.72m
  • Website: https://www.utahmed.com

Number of Employees


Location

  • Utah Medical Products, Inc.
  • 7043 South 300 West
  • Midvale
  • Utah
  • 84047
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
UTMDNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDDec 1982

Biography

Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry in the United States, Europe, and internationally. The company offers fetal monitoring access ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/13 23:57
End of Day Share Price2019/12/13 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.